

Teresa T Cabrera

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7119360/publications.pdf>

Version: 2024-02-01

69
papers

5,035
citations

117571

34
h-index

114418

63
g-index

71
all docs

71
docs citations

71
times ranked

4501
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Implications for immunosurveillance of altered HLA class I phenotypes in human tumours. Trends in Immunology, 1997, 18, 89-95. | 7.5 | 708 |
| 2 | Natural history of HLA expression during tumour development. Trends in Immunology, 1993, 14, 491-499. | 7.5 | 432 |
| 3 | The selection of tumor variants with altered expression of classical and nonclassical MHC class I molecules: implications for tumor immune escape. Cancer Immunology, Immunotherapy, 2004, 53, 904-10. | 2.0 | 239 |
| 4 | HLA class I antigen abnormalities and immune escape by malignant cells. Seminars in Cancer Biology, 2002, 12, 3-13. | 4.3 | 233 |
| 5 | Hard and soft lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. International Journal of Cancer, 2010, 127, 249-256. | 2.3 | 232 |
| 6 | Total loss of MHC class I in colorectal tumors can be explained by two molecular pathways: β 2-microglobulin inactivation in MSI-positive tumors and LMP7/TAP2 downregulation in MSI-negative tumors. Tissue Antigens, 2003, 61, 211-219. | 1.0 | 134 |
| 7 | Mutations of the β 2-microglobulin gene result in a lack of HLA class I molecules on melanoma cells of two patients immunized with MAGE peptides. Tissue Antigens, 1998, 52, 520-529. | 1.0 | 132 |
| 8 | The HLA crossroad in tumor immunology. Human Immunology, 2000, 61, 65-73. | 1.2 | 129 |
| 9 | MHC Class I Antigens and Immune Surveillance in Transformed Cells. International Review of Cytology, 2007, 256, 139-189. | 6.2 | 128 |
| 10 | High frequency of altered HLA class I phenotypes in invasive breast carcinomas. Human Immunology, 1996, 50, 127-134. | 1.2 | 126 |
| 11 | Hla Class I Antigens in Human Tumors. Advances in Cancer Research, 1995, 67, 155-195. | 1.9 | 121 |
| 12 | Analysis of HLA class I expression in progressing and regressing metastatic melanoma lesions after immunotherapy. Immunogenetics, 2008, 60, 439-447. | 1.2 | 119 |
| 13 | Role of Altered Expression of HLA Class I Molecules in Cancer Progression. Advances in Experimental Medicine and Biology, 2007, 601, 123-131. | 0.8 | 117 |
| 14 | Coordinated downregulation of the antigen presentation machinery and HLA class I/ β 2-microglobulin complex is responsible for HLA-ABC loss in bladder cancer. International Journal of Cancer, 2005, 113, 605-610. | 2.3 | 116 |
| 15 | Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. Cancer Immunology, Immunotherapy, 2002, 51, 389-396. | 2.0 | 105 |
| 16 | Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. , 1999, 83, 91-97. | | 104 |
| 17 | Analysis of HLA expression in human tumor tissues. Cancer Immunology, Immunotherapy, 2003, 52, 1-9. | 2.0 | 98 |
| 18 | Presence of hpv 16 sequences in laryngeal carcinomas. International Journal of Cancer, 1990, 46, 8-11. | 2.3 | 97 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 400-406. | 2.0 | 88 |
| 20 | High frequency of altered HLA class I phenotypes in invasive colorectal carcinomas. <i>Tissue Antigens</i> , 1998, 52, 114-123. | 1.0 | 84 |
| 21 | HLA class I expression in metastatic melanoma correlates with tumor development during autologous vaccination. <i>Cancer Immunology, Immunotherapy</i> , 2007, 56, 709-717. | 2.0 | 78 |
| 22 | Distribution of HLA class I altered phenotypes in colorectal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21. <i>Immunogenetics</i> , 2004, 56, 244-53. | 1.2 | 77 |
| 23 | Frequent loss of heterozygosity in the Î²2-microglobulin region of chromosome 15 in primary human tumors. <i>Immunogenetics</i> , 2011, 63, 65-71. | 1.2 | 75 |
| 24 | Regression of melanoma metastases after immunotherapy is associated with activation of antigen presentation and interferon-mediated rejection genes. <i>International Journal of Cancer</i> , 2012, 131, 387-395. | 2.3 | 75 |
| 25 | Expression of HLA G in human tumors is not a frequent event. , 1999, 81, 512-518. | | 65 |
| 26 | Analysis of NK cells and chemokine receptors in tumor infiltrating CD4 T lymphocytes in human renal carcinomas. <i>Cancer Immunology, Immunotherapy</i> , 2005, 54, 858-866. | 2.0 | 62 |
| 27 | Molecular strategies to define HLA haplotype loss in microdissected tumor cells. <i>Human Immunology</i> , 2000, 61, 1001-1012. | 1.2 | 58 |
| 28 | LOH at 6p21.3 region and HLA class altered phenotypes in bladder carcinomas. <i>Immunogenetics</i> , 2006, 58, 503-510. | 1.2 | 56 |
| 29 | Regressing and progressing metastatic lesions: resistance to immunotherapy is predetermined by irreversible HLA class I antigen alterations. <i>Cancer Immunology, Immunotherapy</i> , 2008, 57, 1727-1733. | 2.0 | 56 |
| 30 | HLA and melanoma: multiple alterations in HLA class I and II expression in human melanoma cell lines from ESTDAB cell bank. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1507-1515. | 2.0 | 53 |
| 31 | Biological Implications of HLA-DR Expression in Tumours. <i>Scandinavian Journal of Immunology</i> , 1995, 41, 398-406. | 1.3 | 52 |
| 32 | Bacillus Calmette-Guérin immunotherapy of bladder cancer induces selection of human leukocyte antigen class I-deficient tumor cells. <i>International Journal of Cancer</i> , 2011, 129, 839-846. | 2.3 | 52 |
| 33 | Can the HLA phenotype be used as a prognostic factor in breast carcinomas?. <i>International Journal of Cancer</i> , 1991, 47, 146-154. | 2.3 | 50 |
| 34 | HLA class I expression and HPV-16 sequences in premalignant and malignant lesions of the cervix. <i>Tissue Antigens</i> , 1993, 41, 65-71. | 1.0 | 46 |
| 35 | Characterization of a gastric tumor cell line defective in MHC class I inducibility by both Î± and Î³-interferon. <i>Tissue Antigens</i> , 1996, 47, 391-398. | 1.0 | 45 |
| 36 | High frequency of altered HLA class I phenotypes in laryngeal carcinomas. <i>Human Immunology</i> , 2000, 61, 499-506. | 1.2 | 43 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 37 | Analysis of the expression of HLA class I, proinflammatory cytokines and chemokines in primary tumors from patients with localized and metastatic renal cell carcinoma. <i>Tissue Antigens</i> , 2006, 68, 303-310. | 1.0 | 35 |
| 38 | Frequent HLA class I alterations in human prostate cancer: molecular mechanisms and clinical relevance. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 47-59. | 2.0 | 35 |
| 39 | Analysis of HLAâ€œABC locus-specific transcription in normal tissues. <i>Immunogenetics</i> , 2010, 62, 711-719. | 1.2 | 33 |
| 40 | A Transcriptome-proteome Integrated Network Identifies Endoplasmic Reticulum thiol oxidoreductase (ERp57) as a Hub that Mediates Bone Metastasis. <i>Molecular and Cellular Proteomics</i> , 2013, 12, 2111-2125. | 2.5 | 32 |
| 41 | Impaired surface antigen presentation in tumors: implications for T cell-based immunotherapy. <i>Seminars in Cancer Biology</i> , 2002, 12, 15-24. | 4.3 | 31 |
| 42 | Analysis of KIR gene frequencies in HLA class I characterised bladder, colorectal and laryngeal tumours. <i>Tissue Antigens</i> , 2007, 69, 220-226. | 1.0 | 31 |
| 43 | HLA class I expression in bladder carcinomas. <i>Tissue Antigens</i> , 2003, 62, 324-327. | 1.0 | 30 |
| 44 | A nucleotide insertion in exon 4 is responsible for the absence of expression of an HLA-A*0301 allele in a prostate carcinoma cell line. <i>Immunogenetics</i> , 2001, 53, 606-610. | 1.2 | 29 |
| 45 | High frequency of HLA-B44 allelic losses in human solid tumors. <i>Human Immunology</i> , 2003, 64, 941-950. | 1.2 | 26 |
| 46 | Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. <i>Tissue Antigens</i> , 2007, 69, 264-268. | 1.0 | 26 |
| 47 | Molecular analysis of MHC-class-I alterations in human tumor cell lines. <i>International Journal of Cancer</i> , 1991, 47, 123-130. | 2.3 | 25 |
| 48 | HLA molecules in basal cell carcinoma of the skin. <i>Immunobiology</i> , 1992, 185, 440-452. | 0.8 | 25 |
| 49 | Microsatellite instability analysis in tumors with different mechanisms for total loss of HLA expression. <i>Cancer Immunology, Immunotherapy</i> , 2000, 48, 684-690. | 2.0 | 21 |
| 50 | Higher HLA class I expression in renal cell carcinoma than in autologous normal tissue. <i>Tissue Antigens</i> , 2010, 75, 110-118. | 1.0 | 21 |
| 51 | Leukocyte infiltrate in gastrointestinal adenocarcinomas is strongly associated with tumor microsatellite instability but not with tumor immunogenicity. <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 869-882. | 2.0 | 19 |
| 52 | HLA Class I and II Expression in Rhabdomyosarcomas. <i>Immunobiology</i> , 1991, 182, 440-448. | 0.8 | 18 |
| 53 | K-ras mutations (codon 12) are not involved in down-regulation of mhc class-i genes in colon carcinomas. <i>International Journal of Cancer</i> , 1990, 46, 426-431. | 2.3 | 17 |
| 54 | Loss of HLA Heavy Chain and beta2-Microglobulin in HLA Negative Tumours. <i>Scandinavian Journal of Immunology</i> , 1991, 34, 147-152. | 1.3 | 17 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | Looking for HLA-G expression in human tumours. <i>Journal of Reproductive Immunology</i> , 1999, 43, 263-273. | 0.8 | 13 |
| 56 | ? 2 -microglobulin gene mutation is not a common mechanism of HLA class I total loss in human tumors. <i>International Journal of Clinical and Laboratory Research</i> , 2000, 30, 87-92. | 1.0 | 13 |
| 57 | Class II HLA Antigen Expression in Familial Polyposis Coli is Related to the Degree of Dysplasia. <i>Immunobiology</i> , 1990, 180, 138-148. | 0.8 | 11 |
| 58 | A Monoclonal Antibody GR2110 Reactive With a P24 Antigen Present in a Subgroup of Acute Lymphoid Leukemias. <i>Hybridoma</i> , 1985, 4, 369-378. | 0.9 | 9 |
| 59 | Cytotoxic effects of alkaline tetrasodium EDTA irrigating solutions. <i>Journal of Oral Science</i> , 2020, 62, 285-287. | 0.7 | 5 |
| 60 | Serum Cytokine Profiles of Melanoma Patients and Their Association with Tumor Progression and Metastasis. <i>Journal of Oncology</i> , 2021, 2021, 1-9. | 0.6 | 4 |
| 61 | HLA Class I Expression, Tumor Escape and Cancer Progression. <i>Current Cancer Therapy Reviews</i> , 2008, 4, 105-110. | 0.2 | 3 |
| 62 | MHC Class I Antigens In Malignant Cells. , 2013, , . | | 3 |
| 63 | HLA-DRB1 $\hat{=}$ 16:01 and HLA-DQB1 $\hat{=}$ 05:02 Alleles Influence the Susceptibility and Progression of Cutaneous Malignant Melanoma. <i>Journal of Oncology</i> , 2021, 2021, 1-7. | 0.6 | 3 |
| 64 | Chromosome loss is the most frequent mechanism contributing to HLA haplotype loss in human tumors. <i>International Journal of Cancer</i> , 1999, 83, 91-97. | 2.3 | 3 |
| 65 | “Hard” and “soft” lesions underlying the HLA class I alterations in cancer cells: Implications for immunotherapy. , 2010, 127, 249. | | 1 |
| 66 | Upmodulation by estrogen of HLA class I expression in breast tumor cell lines. <i>Human Immunology</i> , 1994, 39, 129. | 1.2 | 0 |
| 67 | HLA Class I Expression in Human Cancer. , 2013, , 13-30. | | 0 |
| 68 | MHC Class I Antigens and the Tumor Microenvironment. , 2013, , 253-286. | | 0 |
| 69 | Overview of MHC Class I Antigens. , 2013, , 1-11. | | 0 |